Zura Bio Ltd. (ZURA)
4.04
-0.12
(-2.88%)
USD |
NASDAQ |
Sep 25, 16:00
4.045
0.00 (0.00%)
After-Hours: 19:59
Zura Bio Enterprise Value : 180.37M for Sept. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 25, 2026 | 180.37M |
| September 24, 2026 | 191.82M |
| September 23, 2026 | 208.05M |
| September 22, 2026 | 225.22M |
| September 21, 2026 | 224.27M |
| September 18, 2026 | 220.45M |
| September 17, 2026 | 230.95M |
| September 16, 2026 | 234.76M |
| September 15, 2026 | 265.30M |
| September 14, 2026 | 292.02M |
| September 11, 2026 | 292.02M |
| September 10, 2026 | 308.24M |
| September 09, 2026 | 339.73M |
| September 08, 2026 | 379.81M |
| September 04, 2026 | 389.35M |
| September 03, 2026 | 355.95M |
| September 02, 2026 | 335.91M |
| September 01, 2026 | 334.00M |
| August 31, 2026 | 323.51M |
| August 28, 2026 | 340.68M |
| August 27, 2026 | 353.09M |
| August 26, 2026 | 366.45M |
| August 25, 2026 | 397.94M |
| August 24, 2026 | 396.03M |
| August 21, 2026 | 353.09M |
| Date | Value |
|---|---|
| August 20, 2026 | 343.55M |
| August 19, 2026 | 352.13M |
| August 18, 2026 | 345.45M |
| August 17, 2026 | 336.87M |
| August 14, 2026 | 326.37M |
| August 13, 2026 | 332.09M |
| August 12, 2026 | 346.41M |
| August 11, 2026 | 325.42M |
| August 10, 2026 | 332.09M |
| August 07, 2026 | 364.06M |
| August 06, 2026 | 339.73M |
| August 05, 2026 | 333.05M |
| August 04, 2026 | 337.82M |
| August 03, 2026 | 321.60M |
| July 31, 2026 | 313.01M |
| July 30, 2026 | 323.51M |
| July 29, 2026 | 301.56M |
| July 28, 2026 | 323.51M |
| July 27, 2026 | 308.24M |
| July 24, 2026 | 293.93M |
| July 23, 2026 | 299.65M |
| July 22, 2026 | 310.15M |
| July 21, 2026 | 336.87M |
| July 20, 2026 | 296.79M |
| July 17, 2026 | 314.92M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| NovelStem International Corp. | 2.228M |
| Brainstorm Cell Therapeutics, Inc. | 12.06M |
| Summit Therapeutics, Inc. | 11.71B |
| Kezar Life Sciences, Inc. | -11.12M |
| Protara Therapeutics, Inc. | 54.05M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.30M |
| Total Expenses (Quarterly) | 26.30M |
| EPS Diluted (Quarterly) | -0.2074 |
| Earnings Yield | -31.14% |
| Normalized Earnings Yield | -31.14 |